Last reviewed · How we verify
GD2-targeted CAR-T cells
At a glance
| Generic name | GD2-targeted CAR-T cells |
|---|---|
| Sponsor | Sinobioway Cell Therapy Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (PHASE1)
- Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer (EARLY_PHASE1)
- Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial (PHASE1)
- Combination Immunotherapy Targeting Melanoma (PHASE1, PHASE2)
- 3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN (PHASE1)
- Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma (PHASE1)
- Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma (PHASE1)
- CAR T Cells to Target GD2 for DMG (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |